

GLAXOSMITHKLINE PLC

Form 6-K

January 20, 2015

FORM 6-K/A

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending January 2015

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No ☒

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging
Managerial Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline 2009 Performance Share Plan (the Plan) notified the Company and the under-mentioned Directors, Persons Discharging Managerial Responsibilities (PDMR) and Connected Persons on 16 January 2015 of the following increases in their notional interests in Ordinary Shares at a price of 1427.50 pence per Ordinary Share and American Depositary Shares (ADSs) at a price of \$43.19 per ADS following the notional re-investment of the dividend paid to shareholders on 8 January 2015.

Director/PDMR	Ordinary Shares	ADSs
Sir Andrew Witty	18,634.726	
Dr M M Slaoui		5,838.447
Mr S Dingemans	7,826.922	
Mr R G Connor	2,559.691	
Mrs D P Connelly		2,427.946
Mr N Hirons		314.028
Mr S A Hussain	6,349.257	
Mr W C Louv		1,712.688
Mr D S Redfern	2,695.290	
Ms C Thomas	3,719.918	
Mr P C Thomson	1,814.523	
Mr D E Troy		3,469.890
Dr P J T Vallance	7,749.851	
Ms E Walmsley	4,505.102	
Mrs V A Whyte	515.784	

Connected Person	Ordinary Shares	ADSs
Dr K Slaoui (connected person to Dr M M Slaoui)		88.247
Mrs K Thomson (connected person to Mr P C Thomson)	84.998	

The notional dividends accrued will be paid out in proportion to the percentage of participants' Plan holdings that vest following the end of the relevant measurement period.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).

V A Whyte
Company Secretary
19 January 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: January 19, 2015

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc